14,725 Shares in INmune Bio, Inc. (NASDAQ:INMB) Bought by Jane Street Group LLC

Jane Street Group LLC purchased a new position in shares of INmune Bio, Inc. (NASDAQ:INMB) in the third quarter, according to its most recent filing with the SEC. The firm purchased 14,725 shares of the company’s stock, valued at approximately $79,000. Jane Street Group LLC owned 0.07% of INmune Bio at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Financial Advocates Investment Management boosted its position in shares of INmune Bio by 17.4% during the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after purchasing an additional 2,000 shares in the last quarter. Rhumbline Advisers acquired a new position in INmune Bio in the second quarter valued at approximately $121,000. Fermata Advisors LLC boosted its holdings in shares of INmune Bio by 25.2% during the 3rd quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after buying an additional 8,590 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after buying an additional 32,511 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after acquiring an additional 89,091 shares in the last quarter. 12.72% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on INMB. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock. Raymond James initiated coverage on shares of INmune Bio in a research report on Friday, September 27th. They set an “outperform” rating and a $18.00 price objective on the stock.

INmune Bio Stock Performance

INMB stock opened at $6.28 on Thursday. The company has a market capitalization of $139.24 million, a P/E ratio of -2.88 and a beta of 1.78. INmune Bio, Inc. has a 52-week low of $4.32 and a 52-week high of $14.74. The business has a 50-day simple moving average of $5.12 and a two-hundred day simple moving average of $6.11.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same quarter in the prior year, the business earned ($0.48) EPS. As a group, sell-side analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.